<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616079</url>
  </required_header>
  <id_info>
    <org_study_id>R6490-HV-1946</org_study_id>
    <secondary_id>2020-003261-19</secondary_id>
    <nct_id>NCT04616079</nct_id>
  </id_info>
  <brief_title>Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of REGN6490 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of single&#xD;
      ascending intravenous (IV) and subcutaneous (SC) doses of REGN6490 in healthy adult&#xD;
      participants&#xD;
&#xD;
      The secondary objectives of the study are to:&#xD;
&#xD;
        -  Characterize the pharmacokinetic (PK) profile of single IV and SC doses of REGN6490 in&#xD;
           healthy adult participants&#xD;
&#xD;
        -  Assess immunogenicity of REGN6490 in healthy adult participants dosed with a single IV&#xD;
           or SC dose of REGN6490&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision&#xD;
  </why_stopped>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>TEAEs include abnormal laboratory testing, vital signs and electrocardiograms (ECGs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of REGN6490 over time</measure>
    <time_frame>Up to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent REGN6490 Anti-Drug Antibodies (ADAs)</measure>
    <time_frame>Up to Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>IV Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous (IV) dose 1 of REGN6490 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose 2 of REGN6490 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose 3 of REGN6490 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose 4 of REGN6490 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose 5 of REGN6490 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous (SC) dose 1 of REGN6490 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC dose 2 of REGN6490 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC dose 2 of REGN6490 or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN6490</intervention_name>
    <description>Single dose of REGN6490</description>
    <arm_group_label>IV Cohort 1</arm_group_label>
    <arm_group_label>IV Cohort 2</arm_group_label>
    <arm_group_label>IV Cohort 3</arm_group_label>
    <arm_group_label>IV Cohort 4</arm_group_label>
    <arm_group_label>IV Cohort 5</arm_group_label>
    <arm_group_label>SC Cohort 1</arm_group_label>
    <arm_group_label>SC Cohort 2</arm_group_label>
    <arm_group_label>SC Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching single dose of REGN6490</description>
    <arm_group_label>IV Cohort 1</arm_group_label>
    <arm_group_label>IV Cohort 2</arm_group_label>
    <arm_group_label>IV Cohort 3</arm_group_label>
    <arm_group_label>IV Cohort 4</arm_group_label>
    <arm_group_label>IV Cohort 5</arm_group_label>
    <arm_group_label>SC Cohort 1</arm_group_label>
    <arm_group_label>SC Cohort 2</arm_group_label>
    <arm_group_label>SC Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Body mass index between 18 and 31 kg/m2 (inclusive) at screening visit&#xD;
&#xD;
          2. Is judged by the investigator to be in good health based on medical history, physical&#xD;
             examination, vital sign measurements, and ECG's performed at screening and/or prior to&#xD;
             administration of initial dose of study drug&#xD;
&#xD;
          3. Is in good health based on laboratory safety testing obtained at the screening visit&#xD;
&#xD;
          4. Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
          5. Provide informed consent signed by study participant&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. History of clinically significant cardiovascular, dermatological, respiratory,&#xD;
             hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or&#xD;
             neurological disease, as assessed by the investigator, that may confound the results&#xD;
             of the study or poses an additional risk to the participant by study participation&#xD;
&#xD;
          2. Presents any concern to the study investigator that might confound the results of the&#xD;
             study or poses an additional risk to the participant by their participation in the&#xD;
             study&#xD;
&#xD;
          3. Has any physical examination findings and/or history of any illness that, in the&#xD;
             opinion of the study investigator, might confound the results of the study or poses an&#xD;
             additional risk to the participant by study participation&#xD;
&#xD;
          4. Hospitalization (&gt;24 hours) for any reason within 30 days of the screening visit&#xD;
&#xD;
          5. Is a current smoker, including e-cigarettes. Former smokers may be enrolled if they&#xD;
             have stopped smoking for at least 3 months (90 days) prior to the screening visit&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (eg, FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

